Literature DB >> 16352924

[Attempts to improve organ preservation in patients with squamous cell carcinoma of the head and neck].

Takahide Taguchi1, Mamoru Tsukuda.   

Abstract

When surgical resections are performed for patients with locally advanced head and neck cancer, a critical consideration is which organs and functions of patients are sacrificed. In attempts to improve the organ preservation rate in patients with advanced squamous cell carcinoma of the head and neck (SCCHN), chemotherapy has been used either before(neoadjuvant or induction), with (concurrent or concomitant), after (adjuvant) radiotherapy, or as alternating treatment with radiotherapy. A recent systematic review using meta-analysis has revealed that concurrent chemotherapy with radiotherapy shows a significant benefit for the survival rate of patients with SCCHN when compared with radiotherapy alone, and is superior to neoadjuvant chemotherapy. However, no standard concurrent chemoradiotherapy regimen has been defined,although concurrent chemotherapy together with regimens including cisplatin has been considered to be most effective for SCCHN. We combined radiotherapy concurrently with chemotherapy including cisplatin, 5-fluorouracil, methotrexate, and leucovorin in patients with advanced resectable SCC of the hypopharynx to minimize the necessity of radical surgery and preserve the functional larynx. In conclusion, previous reports and our data show that an organ preservation treatment approach using concurrent chemoradiotherapy is feasible.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16352924

Source DB:  PubMed          Journal:  Gan To Kagaku Ryoho        ISSN: 0385-0684


  2 in total

1.  Inhibitory effects of cucurbitacin B on laryngeal squamous cell carcinoma.

Authors:  Tingyan Liu; Meixia Zhang; Hongliang Zhang; Chunyan Sun; Yihui Deng
Journal:  Eur Arch Otorhinolaryngol       Date:  2008-02-29       Impact factor: 2.503

2.  Liriodenine induces the apoptosis of human laryngocarcinoma cells via the upregulation of p53 expression.

Authors:  Liang Li; Ying Xu; Binquan Wang
Journal:  Oncol Lett       Date:  2014-12-29       Impact factor: 2.967

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.